66 related articles for article (PubMed ID: 31437779)
1. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
[TBL] [Abstract][Full Text] [Related]
2. Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
Yang Y; Lv G; Xiu R; Yang H; Wang W; Yu P; Zhang J; Ye L; Wang H; Tian J
Eur J Med Chem; 2024 May; 271():116400. PubMed ID: 38626524
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
Pollock JA; Wardell SE; Parent AA; Stagg DB; Ellison SJ; Alley HM; Chao CA; Lawrence SA; Stice JP; Spasojevic I; Baker JG; Kim SH; McDonnell DP; Katzenellenbogen JA; Norris JD
Nat Chem Biol; 2016 Oct; 12(10):795-801. PubMed ID: 27501397
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells.
Qin Z; Ou S; Xu L; Sorensen K; Zhang Y; Hu DP; Yang Z; Hu WY; Chen F; Prins GS
Chem Biol Drug Des; 2021 May; 97(5):1059-1078. PubMed ID: 33470049
[TBL] [Abstract][Full Text] [Related]
6. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
Gustafson JL; Neklesa TK; Cox CS; Roth AG; Buckley DL; Tae HS; Sundberg TB; Stagg DB; Hines J; McDonnell DP; Norris JD; Crews CM
Angew Chem Int Ed Engl; 2015 Aug; 54(33):9659-62. PubMed ID: 26083457
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Anti-Resistance AR Antagonists Guided by Funnel Metadynamics Simulation.
Chen H; Zhou Y; Wang X; Chai X; Wang Z; Wang E; Xu L; Hou T; Li D; Duan M
Adv Sci (Weinh); 2024 May; 11(19):e2309261. PubMed ID: 38481034
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic Diterpenoids Selectively Suppress Androgen Receptor-Positive Prostate Cancer Cells.
Sekhon I; Chen G; Piri K; Shinkawa S; Ashong D; Zhang Q; Wang G; Chen QH
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375297
[TBL] [Abstract][Full Text] [Related]
9. BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.
Sugawara T; Lejeune P; Köhr S; Neuhaus R; Faus H; Gelato KA; Busemann M; Cleve A; Lücking U; von Nussbaum F; Brands M; Mumberg D; Jung K; Stephan C; Haendler B
Oncotarget; 2016 Feb; 7(5):6015-28. PubMed ID: 26760770
[TBL] [Abstract][Full Text] [Related]
10. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Xiang W; Zhao L; Han X; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Kirchhoff PD; Wang L; Matvekas A; He M; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(18):13487-13509. PubMed ID: 34473519
[TBL] [Abstract][Full Text] [Related]
11. Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.
Buck SAJ; Van Hemelryk A; de Ridder C; Stuurman D; Erkens-Schulze S; van 't Geloof S; Teubel WJ; Koolen SLW; Martens-Uzunova ES; van Royen ME; de Wit R; Mathijssen RHJ; van Weerden WM
Mol Cancer Ther; 2024 May; 23(5):711-720. PubMed ID: 38030379
[TBL] [Abstract][Full Text] [Related]
12. Novel Inhibitors of androgen receptor's DNA binding domain identified using an ultra-large virtual screening.
Radaeva M; Morin H; Pandey M; Ban F; Guo M; LeBlanc E; Lallous N; Cherkasov A
Mol Inform; 2023 Aug; 42(8-9):e2300026. PubMed ID: 37193651
[TBL] [Abstract][Full Text] [Related]
13. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.
Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K
Mol Oncol; 2024 Apr; ():. PubMed ID: 38600681
[TBL] [Abstract][Full Text] [Related]
14. Discovery of
Chai X; Sun H; Zhou W; Chen C; Shan L; Yang Y; He J; Pang J; Yang L; Wang X; Cui S; Fu Y; Xu X; Xu L; Yao X; Li D; Hou T
J Med Chem; 2022 Feb; 65(3):2507-2521. PubMed ID: 35077161
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.
Joseph JD; Wittmann BM; Dwyer MA; Cui H; Dye DA; McDonnell DP; Norris JD
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12178-83. PubMed ID: 19574450
[TBL] [Abstract][Full Text] [Related]
16. Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.
Hammer S; Schlicker A; Zitzmann-Kolbe S; Baumgart S; Hagemann UB; Scholz A; Haendler B; Lejeune P; Karlsson J; Ellingsen C; Hennekes H; Nielsen CH; Juul MU; Mumberg D; Schatz CA
Clin Cancer Res; 2021 Aug; 27(15):4367-4378. PubMed ID: 34035067
[TBL] [Abstract][Full Text] [Related]
17. YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy.
Lam W; Arammash M; Cai W; Guan F; Jiang Z; Liu SH; Cheng P; Cheng YC
Front Pharmacol; 2023; 14():1244655. PubMed ID: 37860121
[No Abstract] [Full Text] [Related]
18. 3-
Wu S; Chen G; Zhang Q; Wang G; Chen QH
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770829
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates.
George A; Raji I; Cinar B; Kucuk O; Oyelere AK
Bioorg Med Chem; 2018 May; 26(8):1481-1487. PubMed ID: 29456113
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide.
Podgoršek E; Mehra N; van Oort IM; Somford DM; Boerrigter E; van Erp NP
Clin Pharmacokinet; 2023 Aug; 62(8):1049-1061. PubMed ID: 37458966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
